Payment overview · 2025
General Payments
$859.17
37 reported records · 13 companies
Healthcare provider profile · identity verified
Puneet Sud, MD
Allopathic & Osteopathic Physicians|General Practice · PROVIDENCE, RI · NPI 1598762346
Verified facts
What the public records show
CMS Open Payments records show Puneet Sud, MD received $859.17 in general payments during 2025 across 37 reported records.
Novo Nordisk Inc accounted for 22.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 23 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Mounjaro, Ozempic, Rybelsus.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 102 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $194.01 | 22.6% | 9 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $167.63 | 19.5% | 5 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $131.09 | 15.3% | 5 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $89.40 | 10.4% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $68.07 | 7.9% | 3 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $48.19 | 5.6% | 3 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $41.18 | 4.8% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $24.84 | 2.9% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $22.16 | 2.6% | 1 | 2025 |
| Braeburn Inc. | Unresolved — no canonical attribution shown | $19.43 | 2.3% | 1 | 2025 |
| EVOKE PHARMA, INC. | Unresolved — no canonical attribution shown | $18.02 | 2.1% | 1 | 2025 |
| Currax Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $17.95 | 2.1% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $17.20 | 2.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $859.17 | 37 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $172.80 | 8 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $172.80 | 8 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $145.38 | 4 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $71.17 | 3 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $60.72 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $59.92 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $49.59 | 2 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $48.19 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $47.64 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $45.38 | 3 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $45.38 | 3 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $41.18 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $28.68 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $28.68 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $24.84 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $24.84 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $22.25 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $21.21 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $20.43 | 1 | 2025 |
Source payment records
|
|||||
| BRIXADI Normalized: brixadi |
Drug | Braeburn Inc. | $19.43 | 1 | 2025 |
Source payment records
|
|||||
| GIMOTI Normalized: gimoti |
Drug | EVOKE PHARMA, INC. | $18.02 | 1 | 2025 |
Source payment records
|
|||||
| CONTRAVE Normalized: contrave |
Drug | Currax Pharmaceuticals LLC | $17.95 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $17.20 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 51 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 26 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
44 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
51 | 14 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
102 | 15 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 580 | 147 |
| Amlodipine Besylate | Amlodipine Besylate | 321 | 86 |
| Lisinopril | Lisinopril | 295 | 73 |
| Omeprazole | Omeprazole | 241 | 66 |
| Alprazolam | Alprazolam | 212 | 49 |
| Levothyroxine Sodium | Levothyroxine Sodium | 192 | 50 |
| Losartan Potassium | Losartan Potassium | 188 | 48 |
| Simvastatin | Simvastatin | 167 | 42 |
| Furosemide | Furosemide | 157 | 42 |
| Clonazepam | Clonazepam | 153 | 25 |
| Metformin Hcl Er | Metformin Hcl | 152 | 44 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 147 | 35 |
| Metoprolol Tartrate | Metoprolol Tartrate | 134 | 40 |
| Pantoprazole Sodium | Pantoprazole Sodium | 129 | 36 |
| Metformin Hcl | Metformin Hcl | 122 | 35 |
| Atenolol | Atenolol | 120 | 33 |
| Famotidine | Famotidine | 119 | 39 |
| Fluticasone Propionate | Fluticasone Propionate | 118 | 57 |
| Tramadol Hcl | Tramadol Hcl | 107 | 27 |
| Tamsulosin Hcl | Tamsulosin Hcl | 105 | 31 |
| Eliquis | Apixaban | 102 | 15 |
| Hydrochlorothiazide | Hydrochlorothiazide | 99 | 27 |
| Metoprolol Succinate | Metoprolol Succinate | 99 | 28 |
| Gabapentin | Gabapentin | 96 | 22 |
| Oxycodone Hcl | Oxycodone Hcl | 92 | 14 |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 91 | suppressed |
| Meloxicam | Meloxicam | 89 | 20 |
| Lorazepam | Lorazepam | 88 | 13 |
| Methylprednisolone | Methylprednisolone | 88 | 67 |
| Ibuprofen | Ibuprofen | 82 | 23 |
| Montelukast Sodium | Montelukast Sodium | 82 | 24 |
| Sertraline Hcl | Sertraline Hcl | 80 | 22 |
| Trazodone Hcl | Trazodone Hcl | 77 | 17 |
| Diazepam | Diazepam | 72 | 12 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 67 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 66 | 12 |
| Lovastatin | Lovastatin | 63 | 18 |
| Allopurinol | Allopurinol | 62 | 12 |
| Azelastine Hcl | Azelastine Hcl | 60 | 34 |
| Pravastatin Sodium | Pravastatin Sodium | 59 | 16 |
| Chlorthalidone | Chlorthalidone | 58 | 16 |
| Diclofenac Sodium | Diclofenac Sodium | 56 | 14 |
| Enalapril Maleate | Enalapril Maleate | 52 | 12 |
| Jardiance | Empagliflozin | 51 | 14 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 50 | 17 |
| Citalopram Hbr | Citalopram Hydrobromide | 48 | 13 |
| Glimepiride | Glimepiride | 48 | 15 |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 46 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 45 | 13 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 44 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 44 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 43 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 42 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 39 | 13 |
| Ondansetron Hcl | Ondansetron Hcl | 38 | 13 |
| Prednisone | Prednisone | 38 | 15 |
| Ventolin Hfa | Albuterol Sulfate | 38 | suppressed |
| Carvedilol | Carvedilol | 36 | 12 |
| Finasteride | Finasteride | 36 | 12 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 36 | suppressed |
| Methadone Hcl | Methadone Hcl | 34 | suppressed |
| Fenofibrate | Fenofibrate | 32 | suppressed |
| Potassium Chloride | Potassium Chloride | 32 | suppressed |
| Celecoxib | Celecoxib | 31 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 31 | 16 |
| Propranolol Hcl | Propranolol Hcl | 29 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 29 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 28 | suppressed |
| Trulicity | Dulaglutide | 28 | suppressed |
| Amoxicillin | Amoxicillin | 27 | 24 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 27 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 27 | 14 |
| Ozempic | Semaglutide | 26 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 26 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 25 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 25 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 25 | 12 |
| Azithromycin | Azithromycin | 24 | 21 |
| Mounjaro | Tirzepatide | 24 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 24 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 24 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 23 | 16 |
| Fluoxetine Hcl | Fluoxetine Hcl | 22 | suppressed |
| Methocarbamol | Methocarbamol | 22 | 13 |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 22 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 21 | suppressed |
| Latanoprost | Latanoprost | 21 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 21 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 20 | suppressed |
| Mirtazapine | Mirtazapine | 20 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 20 | suppressed |
| Xarelto | Rivaroxaban | 20 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 19 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 19 | 16 |
| Valsartan | Valsartan | 19 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 18 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 18 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 18 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 18 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 18 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 17 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 17 | suppressed |
| Glipizide | Glipizide | 17 | suppressed |
| Naproxen | Naproxen | 17 | 11 |
| Pioglitazone Hcl | Pioglitazone Hcl | 17 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 16 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 16 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 16 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 16 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 15 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 15 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 15 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 15 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 14 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 14 | suppressed |
| Methotrexate | Methotrexate Sodium | 14 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 14 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Cephalexin | Cephalexin | 13 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 13 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 13 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 13 | suppressed |
| Memantine Hcl | Memantine Hcl | 13 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 13 | suppressed |
| Percocet | Oxycodone Hcl/Acetaminophen | 13 | suppressed |
| Risperidone | Risperidone | 13 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 13 | suppressed |
| Spironolactone | Spironolactone | 13 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 13 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 12 | suppressed |
| Butalbital-Aspirin-Caffeine | Butalbital/Aspirin/Caffeine | 12 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 12 | suppressed |
| Rybelsus | Semaglutide | 12 | suppressed |
| Suboxone | Buprenorphine Hcl/Naloxone Hcl | 12 | suppressed |
| Temazepam | Temazepam | 12 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 11 | suppressed |
| Humalog Mix 50-50 Kwikpen | Insulin Lispro Protamin/Lispro | 11 | suppressed |
| Hydrocortisone | Hydrocortisone | 11 | suppressed |
| Januvia | Sitagliptin Phosphate | 11 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $859.17 · 37 records | Novo Nordisk Inc | ABRYSVO, AIRSUPRA, AREXVY, BREZTRI, BRIXADI, COMIRNATY, CONTRAVE, FREESTYLE LIBRE 3, GEMTESA, GIMOTI, JARDIANCE, MOUNJARO, Ozempic, PAXLOVID, PREVNAR 20, QULIPTA, Rybelsus, SHINGRIX, UBRELVY, VRAYLAR, Wegovy, ZEPBOUND, ZORYVE | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error